parallel randomized trial

S003082

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Polycystic ovary syndromeS003082

Design

Randomized: 82
Start year
Treatment: 12 weeks, follow-up 12 weeks
Countries: China (1 sites)
Sponsor: (non industry)
Eligibility: PCOS by Rotterdam criteria; age 18 to 40; overweight or obese by Chinese criteria; diabetes excluded

Conduct and analysis

Blinding: not reported
Sequence generation: computer
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population
Missing data

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Exenatide 10 ug subcutaneous twice daily Exenatide 10 ug twice daily	lifestyle: standard	41	31
A2	Metformin Metformin 1000 mg twice daily	lifestyle: standard	41	32

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Exenatide 10 ug subcutaneous twice daily A1	Metformin A2	Whole trial ALL
age	mean (years)	27.2	27.7
bmi	mean (kg/m2)	28.27	28.66
female	n			82
waist	mean (cm)	91.20	93.40
weight	mean (kg)	71.84	72.04